Article

Michael J. Mauro Discusses the Diagnosis of CML

Author(s):

Michael J. Mauro

Michael J. Mauro, leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses the diagnosis of chronic myeloid leukemia (CML).

Michael J. Mauro, leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses the diagnosis of chronic myeloid leukemia (CML).

Related Videos
Image of man with black hair.
Image of a man with dark hair and some facial hair.
Image of a man with blond facial hair.
Image of woman with blonde hair.
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Related Content
Illustration of blood cells.
November 20th 2024

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

Ryan Scott
The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of woman with brown hair.
November 19th 2024

Newer Therapies for Acute Lymphoblastic Leukemia May Reduce Side Effects

Spencer Feldman Darlene Dobkowski, MA
New treatments for acute lymphoblastic leukemia may lead to fewer side effects than chemotherapy, as they target cancer cells more precisely, an expert said.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of bald man.
November 18th 2024

How Circulating Tumor Cell Count Can Inform Prostate Cancer Treatment

Alex Biese
An expert explained how circulating tumor cell count can identify possible clinical trial participants.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.